What is the significance of the FDA approval for BRUKINSA?

The FDA's accelerated approval of BRUKINSA™ (zanubrutinib) is a major achievement for BeOne Medicines Ltd. as it signifies the first drug discovered by the company to receive regulatory clearance. This approval allows the company to market BRUKINSA for the treatment of mantle cell lymphoma (MCL) in a specific patient population, marking a critical step in its commercialization strategy and its goal of transforming cancer treatments.

What is the approved indication for BRUKINSA?

BRUKINSA™ (zanubrutinib) has received accelerated approval from the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This means the drug can be marketed for patients whose MCL has not responded to or has relapsed after at least one previous treatment regimen.

What is the pricing of BRUKINSA?

The Wholesale Acquisition Price (WAC) for a 30-day supply of BRUKINSA (zanubrutinib) has been established at $12,935. This price point will be a key factor in assessing the drug's commercial performance and market access.

What does 'accelerated approval' mean for investors?

Accelerated approval by the FDA allows for earlier marketing of a drug based on its potential to address unmet medical needs in serious or life-threatening conditions. For investors, this means that BeOne Medicines Ltd. can begin generating revenue from BRUKINSA sooner than with a standard approval process. However, it often comes with a requirement for post-marketing studies to confirm clinical benefit.

ONC/BEIGF 8-K SEC Disclosure

Summary

BeOne Medicines Ltd. (ONC) announced a significant milestone on November 15, 2019, with the U.S. Food and Drug Administration (FDA) granting accelerated approval for BRUKINSA™ (zanubrutinib). This approval, specifically for adult patients with mantle cell lymphoma (MCL) who have undergone at least one prior therapy, marks the first FDA-approved product discovered by BeiGene. This event is a crucial step for the company in achieving its strategic objective of advancing cancer treatment globally. The Wholesale Acquisition Price (WAC) for a 30-day supply of BRUKINSA has been set at $12,935. This pricing, coupled with the accelerated approval, positions BRUKINSA to enter the market and potentially generate revenue. Investors should monitor the commercial uptake and market penetration of BRUKINSA, as well as any further clinical developments or regulatory updates pertaining to this therapy.

Key Highlights

1FDA grants accelerated approval for BRUKINSA™ (zanubrutinib) for Mantle Cell Lymphoma (MCL) in adult patients with at least one prior therapy.
2BRUKINSA™ is the first BeiGene-discovered product to receive FDA approval.
3This approval represents a significant milestone for BeiGene's mission to advance cancer treatments.
4The Wholesale Acquisition Price (WAC) for a 30-day supply of BRUKINSA is set at $12,935.
5The announcement was made on November 14, 2019, and reported in an 8-K filing on November 15, 2019.
6The approved indication is for a specific patient population with relapsed/refractory MCL.

BeOne Medicines Ltd. 8-K Report, Corporate Update (Nov 15, 2019)

Summary

Key Highlights

Frequently Asked Questions